AbbVie submits a regulatory filing for etentamig based on the Phase 3 CERVINO study.
AbbVie reported positive topline Phase 3 CERVINO results for multiple myeloma. The milestone requires public confirmation of an FDA or EMA marketing application.
Across 6 frontier models answering independently, the panel leans yes: the median is 74%.
They do not agree: Gemini puts it at 88% and Claude at 30%, 58 points apart. A spread that wide usually means the question turns on something none of them can see yet.
Nothing is settled until 14 Sept 2027, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GeminiGoogle
With positive Phase 3 topline data already in hand, a 12-month window is standard for BLA/MAA submission.
google/gemini-3.8-flash · asked 14 Sept 202688% -
GrokxAI
Positive P3 already reported; oncology filings typically follow within months, 12-month window is ample.
x-ai/grok-4.6 · asked 14 Sept 202686% -
GPTOpenAI
Positive Phase 3 topline usually leads to filing within a year, but safety/CMC or strategic delays remain.
openai/gpt-5.6-terra · asked 14 Sept 202676% -
QwenAlibaba
Positive P3 data exists; typical NDA/BLA submission within ~12-18 months of results, well within the 12-month window.
qwen/qwen3.8-max-0902 · asked 14 Sept 202672% -
DeepSeekDeepSeek
Positive Phase 3 topline; filing typically follows within 12-18 months, but no filing announced yet.
deepseek/deepseek-v4.1-flash · asked 14 Sept 202645% -
ClaudeAnthropic
Requires 12+ months post-topline for full data package and filing; timeline plausible but not assured by Sept 2027
anthropic/claude-sonnet-5 · asked 14 Sept 202630%
6 of 6 models answered · 58 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 14 Sept 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.